2015
Safety analysis of a phase III randomized trial of chemotherapy with or without bevacizumab (B) in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
Argiris A, Li S, Savvides P, Forastiere A, Burtness B. Safety analysis of a phase III randomized trial of chemotherapy with or without bevacizumab (B) in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). Journal Of Clinical Oncology 2015, 33: 6022-6022. DOI: 10.1200/jco.2015.33.15_suppl.6022.Peer-Reviewed Original Research
2010
Antibody-Based Therapies for Solid Tumors
Shanbhag S, Burtness B. Antibody-Based Therapies for Solid Tumors. Cancer Growth And Progression 2010, 245-256. DOI: 10.1007/978-90-481-9704-0_13.Peer-Reviewed Original ResearchSide effectsHER2-overexpressing breast cancerStandard cytotoxic chemotherapyCell lung cancerEGFR antibody cetuximabAntibody-based therapiesExcess side effectsAnti-VEGF antibodyMechanism of actionMetastatic settingCytotoxic chemotherapyMetastatic colorectalLung cancerColorectal carcinomaBreast cancerAntibody cetuximabVEGF antibodySolid tumorsAntibody trastuzumabClinical useMonoclonal antibodiesCancer therapeuticsCancerAntibodiesBevacizumab